Wirksamkeit eines Eisen-Retardpräparates bei Eisenmangelanämie

TY - JOUR

T1 - Wirksamkeit eines Eisen-Retardpräparates bei Eisenmangelanämie

AU - Nielsen, Peter

AU - Kongi, Rosemarie

AU - Fischer, Roland

PY - 2016/12

Y1 - 2016/12

N2 - OBJECTIVE: To study the therapeutic efficacy of an oral iron retard preparation in patients with iron deficiency anemia.METHODS: In an investigator-initiated open study, 28 patients with iron deficiency anemia were treated with an iron sulfate sustained-release preparation (80 mg iron ions per tablet). The bioavailability was determined from the increase in the haemoglobin value under therapy and the measured blood loss. For the quantification of individual blood losses, a59Fe labeling method was used and the59Fe whole body retention in the observation period was measured with a whole body counter. This established method provides reliable data on the bioavailability of an oral iron preparation used.RESULTS: In all patients the increased iron loss (average 6.6 ± 5.9 mg/d) was easily compensated by the amount of iron (average 11.7 ± 6.6 mg/d) taken with a daily dose of 80 mg of iron. During the observation period of 6-10 weeks there was a significant increase in haemoglobin (Hb) and ferritin concentration (mean increase of Hb from 10.2 ± 1.6 to 12.5 ± 1.5 g/dl and from ferritin from 9 ± 11 to 31 ± 23 μg/L).CONCLUSIONS: Our results show that the iron sulfate retardant preparation used has a high bioavailability for iron. In all patients the anemia could be treated effectively. These findings seem to indicate that patients with chronic iron deficiency anemia can also receive therapeutically administered iron from the distal intestine sections.

AB - OBJECTIVE: To study the therapeutic efficacy of an oral iron retard preparation in patients with iron deficiency anemia.METHODS: In an investigator-initiated open study, 28 patients with iron deficiency anemia were treated with an iron sulfate sustained-release preparation (80 mg iron ions per tablet). The bioavailability was determined from the increase in the haemoglobin value under therapy and the measured blood loss. For the quantification of individual blood losses, a59Fe labeling method was used and the59Fe whole body retention in the observation period was measured with a whole body counter. This established method provides reliable data on the bioavailability of an oral iron preparation used.RESULTS: In all patients the increased iron loss (average 6.6 ± 5.9 mg/d) was easily compensated by the amount of iron (average 11.7 ± 6.6 mg/d) taken with a daily dose of 80 mg of iron. During the observation period of 6-10 weeks there was a significant increase in haemoglobin (Hb) and ferritin concentration (mean increase of Hb from 10.2 ± 1.6 to 12.5 ± 1.5 g/dl and from ferritin from 9 ± 11 to 31 ± 23 μg/L).CONCLUSIONS: Our results show that the iron sulfate retardant preparation used has a high bioavailability for iron. In all patients the anemia could be treated effectively. These findings seem to indicate that patients with chronic iron deficiency anemia can also receive therapeutically administered iron from the distal intestine sections.

KW - Journal Article

KW - English Abstract

U2 - 10.1007/s15006-016-9055-6

DO - 10.1007/s15006-016-9055-6

M3 - SCORING: Zeitschriftenaufsatz

C2 - 27933573

VL - 158

SP - 17

EP - 23

JO - MMW Fortschr Med

JF - MMW Fortschr Med

SN - 1438-3276

IS - Suppl 6

ER -